Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME

Inclusion Criteria: * Informed consent form must be signed before any tests or procedures are done * Male or female of 30 to 80 years of age (inclusive) at the first screening visit * Diagnosis of type 2 diabetes, with fasting blood glucose≤10mmol/L, HbA1C≤10.0% * Diabetic medication must be stable for at least 3 months before first screening visit and remain stable during study * Diagnosis of non-proliferative diabetic retinopathy with diabetic macular edema resulting in visual acuity reduction * Study eye's BCVA between 24 to 78 ETDRS letters at screening and baseline of the study * Macular edema of the study eye and central retinal thickness ≥300 µm determined by SD-OCT * Study eye had not had grid pattern photocoagulation, intraocular surgery, intravitreal corticosteroid injections and intravitreal anti-VEGF injections for at least 3 months before baseline * Non-study eye's BCVA ≥ 24 ETDRS letters at screening and baseline of the study * Non-study eye had not had intravitreal anti-VEGF injections for at least 3 months before baseline * If both eyes qualify, then investigators will choose an eye with worse BCVA as study eye. Only study eye will receive intravitreal ranibizumab and/or Micropulse Laser treatment Exclusion Criteria: * Failure to follow study or follow-up procedures * Pregnant or breast-feeding woman and woman without adequate method of contraception * History of stroke or myocardial infarction within 3 months before screening * Renal failure or creatinine \> 2.0 mg/dl * Uncontrolled systemic diseases or systemic treatment that may affect results of the study * Active ocular or intraocular infections of either eye * Neovascularization of the iris or neovascular glaucoma of either eye * A history of uveitis or vitreous macular traction in study eye * Glaucoma or IOP≥24 mmHg of study eye